A diagnostics company executive is facing federal fraud charges for allegedly bilking investors out of millions by falsely stating that the company was developing a breakthrough test for COVID-19, the US Department of Justice announced recently.
Keith Berman, CEO of Decision Diagnostics Inc., was charged with one count of securities fraud and one count of making...
Welcome to Medtech Insight
Create an account to read this article
Already a subscriber?